Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials

Ruperto N., Brunner H. I., Quartier P., Constantin T., Wulffraat N. M., Horneff G., ...Daha Fazla

ANNALS OF THE RHEUMATIC DISEASES, cilt.77, sa.12, ss.1710-1719, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 77 Sayı: 12
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1136/annrheumdis-2018-213150
  • Dergi Adı: ANNALS OF THE RHEUMATIC DISEASES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1710-1719
  • İstanbul Üniversitesi Adresli: Evet

Özet

Objectives To evaluate the long-term efficacy and safety of canakinumab in patients with active systemic juvenile idiopathic arthritis (JIA).